Research map: Opportunities to improve detection of genetic predisposition for ovarian cancer applying the Tumor-First workflow

Back to the article

Papers in this map

  1. Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive · Mariel K. Casparie · 2007 · 893 citations · Cited by this paper
  2. Colonoscopy findings and polyp pathology in CHEK2 carriers: a single center experience · 2026 · Related
  3. PARP Inhibitors in Ovarian Cancer: A Review · David M. O’Malley · 2023 · 192 citations · Cited by this paper
  4. Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes · 2026 · Related
  5. Germline Genetic Testing After Cancer Diagnosis · Allison W. Kurian · 2023 · 177 citations · Cited by this paper
  6. Attenuated Li–Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report · 2026 · Related
  7. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition · Janet R. Vos · 2019 · 70 citations · Cited by this paper
  8. Patient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome · 2026 · Related
  9. NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas · Robbert D.A. Weren · 2016 · 65 citations · Cited by this paper
  10. Breast cancer phenotypes in carriers of pathogenic POT1 variants · 2026 · Related
  11. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis · Vera M. Witjes · 2021 · 51 citations · Cited by this paper
  12. Homozygous TP53 alterations: a case of a biallelic splice variant and a brief review of the literature · 2026 · Related
  13. Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer · Kelsey S. Lau‐Min · 2023 · 49 citations · Cited by this paper
  14. Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units · 2026 · Related
  15. Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program · Melanie E. Care · 2020 · 19 citations · Cited by this paper
  16. When screentime fails: initiative to improve completion of hereditary cancer genetic testing after telemedicine counseling · 2026 · Related
  17. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective · Kyra Bokkers · 2022 · 18 citations · Cited by this paper
  18. Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy · 2026 · Related
  19. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First? · Vera M. Witjes · 2023 · 13 citations · Cited by this paper
  20. Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas · 2026 · Related
  21. Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients · Caterina Fumagalli · 2022 · 9 citations · Cited by this paper
  22. Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow · Vera M. Witjes · 2024 · 6 citations · Cited by this paper
  23. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma · Emily A. Goebel · 2022 · 5 citations · Cited by this paper
  24. BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients · Lieke Lanjouw · 2023 · 5 citations · Cited by this paper
  25. Evaluation of homologous recombination testing in ovarian carcinoma · Vera M. Witjes · 2026 · 3 citations · Cited by this paper
  26. Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data · Lieke Lanjouw · 2025 · 2 citations · Cited by this paper
  27. Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma · Vera M. Witjes · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)